Tilray(TLRY, $9.57) to merge with Alphria
Canadian cannabis company Tilray Inc. announced plans to merger with Aphria Inc. .The deal would create the world's largest cannabis company by revenue.
CNBC’s Sara Eisen tweeted that a deal announcement could come as early as Wednesday, following a Bloomberg Canada report.
The merged entity would have Tilray as its name, Aphria shareholders would own a larger stake and a majority of the board seats. The all-stock deal will create a company with an equity value of about C$4.8 billion ($3.8 billion). The combined companies’ 12-month annual sales of C$874 million is higher than that of industry leaders such as Curaleaf Holdings Inc. and Canopy Growth Corp.
The merged operation could likely move its headquarters to the U.S. ,according to the report.
TLRY's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TLRY turned positive on July 02, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TLRY's RSI Oscillator exited the oversold zone, of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where TLRY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .
TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for TLRY entered a downward trend on July 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.348) is normal, around the industry mean (46.277). P/E Ratio (0.000) is within average values for comparable stocks, (98.834). TLRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.664). TLRY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (0.545) is also within normal values, averaging (114.521).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis
Industry PharmaceuticalsGeneric
Advertisement